Compare CRSP & SIGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRSP | SIGI |
|---|---|---|
| Founded | 2013 | 1926 |
| Country | Switzerland | United States |
| Employees | N/A | 2800 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.1B |
| IPO Year | 2016 | N/A |
| Metric | CRSP | SIGI |
|---|---|---|
| Price | $50.21 | $90.65 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 5 |
| Target Price | $70.29 | ★ $85.80 |
| AVG Volume (30 Days) | ★ 1.7M | 489.5K |
| Earning Date | 05-11-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 2.03% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $289,590,000.00 | N/A |
| Revenue This Year | $807.72 | $0.41 |
| Revenue Next Year | $172.52 | $4.81 |
| P/E Ratio | ★ N/A | $11.38 |
| Revenue Growth | ★ 9169.85 | N/A |
| 52 Week Low | $35.38 | $71.75 |
| 52 Week High | $78.48 | $91.63 |
| Indicator | CRSP | SIGI |
|---|---|---|
| Relative Strength Index (RSI) | 46.50 | 67.82 |
| Support Level | $44.82 | $76.34 |
| Resistance Level | $60.45 | $91.31 |
| Average True Range (ATR) | 2.49 | 2.16 |
| MACD | -0.37 | 0.47 |
| Stochastic Oscillator | 35.44 | 92.56 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Selective Insurance Group Inc is a regional property-casualty insurer based in New Jersey, with its operations focused in the New York metropolitan area. The Company has four operating segments: Standard Commercial Lines, Standard Personal Lines, E&S Lines, and Investments. Majority of revenue is gained from Standard Commercial Lines segment, which comprises of property and casualty insurance products and services provided in the standard marketplace to commercial enterprises, which are typically businesses, non-profit organizations, and local government agencies.